BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) by Roche is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ HYBREZA is a subcutaneous formulation combining atezolizumab (a PD-L1 checkpoint inhibitor) with hyaluronidase to enable rapid subcutaneous delivery. It is a monoclonal antibody therapeutic that blocks the programmed death receptor-1 pathway to unleash immune responses against cancer cells. This formulation improves upon the original TECENTRIQ by offering faster administration and improved patient convenience.
Growth
As a newly approved formulation (September 2024) in the growth stage, this product offers opportunities for field teams to establish market presence against entrenched peak-stage competitors.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECENTRIQ HYBREZA offers entry and growth opportunities in a high-profile oncology franchise during the critical launch-to-growth transition phase. Teams will focus on positioning subcutaneous convenience and switching existing TECENTRIQ patients, facing significant competition from established players and the concurrent KEYTRUDA QLEX launch.
Brand Manager
Worked on TECENTRIQ HYBREZA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.